INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,104,692 | -65.7% | 78,800 | -58.3% | 0.00% | -50.0% |
| Q2 2023 | $11,954,056 | -5.8% | 188,788 | -19.4% | 0.00% | 0.0% |
| Q1 2023 | $12,687,507 | +9.3% | 234,303 | +6.8% | 0.00% | -33.3% |
| Q4 2022 | $11,612,712 | +2.5% | 219,439 | -9.9% | 0.00% | 0.0% |
| Q3 2022 | $11,332,000 | +1.9% | 243,539 | +25.0% | 0.00% | 0.0% |
| Q2 2022 | $11,116,000 | -28.9% | 194,757 | -23.7% | 0.00% | 0.0% |
| Q1 2022 | $15,625,000 | -63.0% | 255,339 | -68.3% | 0.00% | +200.0% |
| Q4 2021 | $42,190,000 | +111.5% | 806,108 | +50.7% | 0.00% | -66.7% |
| Q3 2021 | $19,944,000 | -8.9% | 534,971 | -0.2% | 0.00% | -25.0% |
| Q2 2021 | $21,886,000 | -12.2% | 536,177 | -27.0% | 0.00% | 0.0% |
| Q1 2021 | $24,921,000 | -50.4% | 734,449 | -53.5% | 0.00% | 0.0% |
| Q4 2020 | $50,198,000 | +39.7% | 1,578,518 | +12.7% | 0.00% | -42.9% |
| Q3 2020 | $35,937,000 | +52.9% | 1,400,524 | +52.9% | 0.01% | +40.0% |
| Q2 2020 | $23,509,000 | +94.2% | 915,822 | +16.3% | 0.01% | +66.7% |
| Q1 2020 | $12,106,000 | -85.3% | 787,599 | -67.2% | 0.00% | -87.0% |
| Q4 2019 | $82,384,000 | +959.3% | 2,401,168 | +130.7% | 0.02% | +666.7% |
| Q3 2019 | $7,777,000 | -84.5% | 1,041,039 | -73.1% | 0.00% | -57.1% |
| Q2 2019 | $50,270,000 | +551.2% | 3,872,868 | +511.1% | 0.01% | +133.3% |
| Q1 2019 | $7,720,000 | -20.5% | 633,800 | -25.6% | 0.00% | 0.0% |
| Q4 2018 | $9,707,000 | -24.5% | 852,200 | +43.9% | 0.00% | -40.0% |
| Q3 2018 | $12,851,000 | +1.6% | 592,227 | -17.3% | 0.01% | 0.0% |
| Q2 2018 | $12,650,000 | +6.5% | 715,926 | +26.8% | 0.01% | +25.0% |
| Q1 2018 | $11,883,000 | +280.6% | 564,504 | +161.7% | 0.00% | +300.0% |
| Q4 2017 | $3,122,000 | -85.1% | 215,686 | -83.8% | 0.00% | -87.5% |
| Q3 2017 | $20,950,000 | +954.4% | 1,327,627 | +730.1% | 0.01% | +700.0% |
| Q2 2017 | $1,987,000 | -44.3% | 159,940 | -27.2% | 0.00% | -50.0% |
| Q1 2017 | $3,570,000 | -28.7% | 219,743 | -33.8% | 0.00% | -33.3% |
| Q4 2016 | $5,008,000 | +76.6% | 331,863 | +78.4% | 0.00% | +200.0% |
| Q3 2016 | $2,835,000 | -77.1% | 186,000 | -41.8% | 0.00% | -83.3% |
| Q2 2016 | $12,399,000 | +279.3% | 319,400 | +171.6% | 0.01% | +200.0% |
| Q1 2016 | $3,269,000 | -55.3% | 117,600 | -13.5% | 0.00% | -33.3% |
| Q4 2015 | $7,313,000 | -29.1% | 135,943 | -47.2% | 0.00% | -25.0% |
| Q3 2015 | $10,310,000 | +372.7% | 257,507 | +277.2% | 0.00% | +300.0% |
| Q2 2015 | $2,181,000 | +1168.0% | 68,262 | +570.5% | 0.00% | – |
| Q2 2014 | $172,000 | – | 10,181 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |